Innovating Alzheimer’s disease diagnostics: blood biomarker technologies

Currently, clinicians use cognitive exams along with diagnostic tools like cerebrospinal fluid (CSF) analysis and PET scans to detect the hallmark protein deposits of Alzheimer's: amyloid plaques and tau tangles. However, these methods can be perceived as invasive and expensive, creating barriers to diagnosis.

Recognizing these challenges, Roche researchers are working on diagnostic innovations to improve the patient journey. One of the most promising areas is the development of simple, accurate blood technologies that can detect key biomarkers associated with Alzheimer's.

"Developing these types of blood biomarker technologies for Alzheimer's diagnostics is a monumental step forward,” said Olivier Gillieron, Life Cycle Leader, Cardiometabolic & Neurology, at Roche. “They have the potential to remove significant barriers, making it possible for more people to get the timely and accurate diagnosis they need to preserve who they are."

These innovations are designed to reduce the time, stress and cost associated with current diagnostic methods.

The end-to-end approach

An end-to-end approach to Alzheimer's disease aims to provide solutions across the entire patient journey, from early detection and diagnosis to treatment and ongoing monitoring. This strategy leverages the integration of diagnostic and pharmaceutical expertise to transform the way we approach this disease. It starts with the idea that earlier diagnosis can lead to more effective disease management.

This is especially important because the biological changes of Alzheimer's, such as the buildup of amyloid-beta plaques and tau tangles, can begin 10 to 20 years before any cognitive symptoms appear. This long asymptomatic phase is a critical window of opportunity for interventions1.

"Our approach integrates diagnostics with pharmaceutical research, allowing us to think about the patient journey as a whole,” Gillieron said. “This is crucial because earlier diagnosis is the key to more effective treatment, especially during that window when we can intervene before cognitive symptoms even appear."

A new generation of diagnostics

This next generation of diagnostic science detects the hallmarks of Alzheimer's disease in a patient's blood.

One innovation assesses the presence of a key protein (Phosphorylated tau 181 (pTau181)) to rule out Alzheimer's as a cause of early-stage cognitive impairment. Another technology aims to identify carriers of the APOE4 gene variant, which is associated with a higher risk of developing late-onset Alzheimer's, the most common form (~95% of cases) typically after 65 years of age2. A third innovation is displaying excellent accuracy and potential in both ruling in and ruling out an Alzheimer's diagnosis by detecting another specific protein (pTau217) in the blood.

The ability to perform these diagnostics in laboratories worldwide is a major advantage. Systems that can run hundreds of analyses per hour and are fully automated can quickly scale diagnostic capabilities once new methods are approved. This scalability ensures that patients can benefit from these innovations as soon as they become available for use.

By bringing these innovations to a global scale, the goal is to ultimately provide individuals and their loved ones with the opportunity to make plans for care and lifestyle changes that will help slow disease progression.